Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company pioneering allogeneic iNKT cell therapies for cancer and immune-mediated diseases. This page provides investors and industry observers with timely updates on material developments, including clinical trial progress, regulatory milestones, and strategic partnerships.
Access verified press releases and news articles covering MiNK Therapeutics' innovative pipeline, manufacturing advancements, and collaborative research initiatives. Content spans earnings announcements, trial data disclosures, executive leadership updates, and scientific presentations relevant to the company’s position in the immunotherapy sector.
Bookmark this page for streamlined tracking of INKT’s progress in developing off-the-shelf cellular therapies. Check regularly for authoritative updates that inform analysis of the company’s scientific and commercial trajectory.
MiNK Therapeutics (NASDAQ: INKT) reported its Q4 and full year 2024 financial results, highlighting progress in developing allogeneic iNKT cell therapies. The company's lead candidate, AgenT-797, showed promising results in cancer treatment and inflammatory lung conditions, with an 80% survival rate in VV ECMO patients versus 10% in hospital controls.
Key developments include a Phase 2 trial in advanced gastric cancer, next-generation PRAME-TCR iNKTs development, and MiNK-215 showing anti-tumor activity in colorectal cancer models. The company secured a research collaboration with Autonomous Therapeutics and raised $5.8M in private financing.
Financial results show a year-end cash balance of $4.6M, reduced cash burn with operations using $9.6M in 2024 compared to $15.8M in 2023. Net loss improved to $10.8M ($2.86 per share) in 2024 from $22.5M ($6.54 per share) in 2023.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its fourth quarter and full year 2024 financial results release for March 18th, 2025, before market opening.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a corporate update and discussion of financial results. Investors can access the call via phone at 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 8023784, or through the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT) presented new translational data from its ongoing Phase 2 study of allo-iNKTs (agenT-797) at the AACR IO Annual Meeting. The study evaluates agenT-797 in combination with botensilimab and balstilimab (BOT/BAL) in patients with refractory gastroesophageal cancer.
The data demonstrated synergy between allo-iNKT cells, checkpoint inhibitors, and chemotherapy, showing robust immune reactivation in unresponsive tumors. Key findings include significant increases in interferon-gamma levels and enhanced tumor infiltration by T cells and antigen-presenting cells. The study revealed that optimal results were achieved when agenT-797 was administered concurrently with checkpoint inhibitors before chemotherapy.
MiNK's allogeneic manufacturing process can generate billions of donor-derived iNKT cells in a single run, producing thousands of doses for global distribution, potentially reducing costs and improving patient access.
MiNK Therapeutics (NASDAQ: INKT) has announced its return to full compliance with Nasdaq Capital Market listing requirements. The company has successfully met both the minimum bid price and market value requirements for continued listing, resolving previous compliance issues.
MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company maintains a pipeline of native and next-generation engineered iNKT programs, with a platform designed for scalable and reproducible manufacturing for off-the-shelf delivery.
MiNK Therapeutics (NASDAQ: INKT) has been selected to present interim data from its ongoing Phase 2 study at the AACR IO Annual Meeting in Los Angeles. The presentation will focus on their investigation of AgenT-797 in combination with botensilimab and balstilimab (BOT/BAL) for treating refractory gastric cancer patients.
The study specifically targets patients with PD-1 refractory gastroesophageal cancer (GEC) who have received second-line or later treatment. The presentation, scheduled for February 25th, will include biomarker analysis from the trial combining iNKT cell therapy with CTLA-4 and PD-1 inhibitors.
MiNK Therapeutics (NASDAQ: INKT) announced a presentation at the ASCO GI Symposium, highlighting their novel combination therapy approach for advanced gastroesophageal cancers. The company is conducting a Phase 2 trial at Memorial Sloan Kettering Cancer Center, combining agenT-797 (iNKT cells) with botensilimab/balstilimab (BOT/BAL) plus ramucirumab and paclitaxel for previously treated patients.
Previous Phase 1 trial data showed durable responses and tolerability in PD-1 refractory cancers, with gastric cancer patients demonstrating significant clinical and immunologic responses. The company plans to provide a clinical update from the ongoing Phase 2 study in the second half of 2025.
CEO Dr. Jennifer Buell emphasized that iNKT cells play a important role in immune reconstitution, while BOT/BAL enhances T-cell priming and eliminates immunosuppressive regulatory cells, creating a comprehensive approach to make disease biologically unsustainable.
MiNK Therapeutics (NASDAQ: INKT) has announced an upcoming presentation at the ASCO GI Symposium in San Francisco from January 23-25, 2025. The presentation will focus on their ongoing Phase 2 study of agenT-797, an invariant natural killer T (iNKT) cell therapy, combined with Agenus' botensilimab/balstilimab for treating refractory gastric cancer.
The abstract (TPS515), titled 'A phase II study of agenT-797, botensilimab, and balstilimab in patients with advanced, refractory gastroesophageal adenocarcinoma,' will be presented by Dr. Samuel Cytryn during the Trials in Progress Poster Session on January 23, 2025. Complete abstracts will be released on January 21st, 2025, at 5:00 PM ET, with presentation materials later available on MiNK's website.
MiNK Therapeutics reported Q3 2024 financial results and business updates. The company ended Q3 with $6.3 million cash balance, with reduced cash burn of $3 million for Q3 and $7.8 million for nine months of 2024. Net loss was $1.8 million ($0.05 per share) for Q3 and $8.3 million ($0.22 per share) for nine months.
Key developments include Dr. Robert Kadlec joining the Board, a research collaboration with Autonomous Therapeutics for metastatic tumors, and two presentations at SITC 2024. The company's Phase 2 trial for gastric cancer is ongoing with data expected in early 2025, and a Phase 1 GvHD trial is planned for 2025.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on invariant natural killer T (iNKT) cell therapies, announced it will release its third quarter 2024 financial results before market opens on November 14, 2024. The company will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update. The event will be accessible via phone and webcast through the company's investor relations website.
MiNK Therapeutics presented new data at SITC 2024 showcasing their iNKT cell therapy programs. Their lead therapy agenT-797, alone or combined with anti-PD-1, demonstrated durable disease control in heavily pretreated patients. When combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, and DLL3, it showed enhanced T-cell activation and tumor cell killing.
The company also presented data on their PRAME-TCR iNKT therapy, designed to treat PRAME-positive solid tumors without requiring lymphodepletion or HLA-matching. A Phase 2 trial of agenT-797 is currently enrolling patients with advanced gastroesophageal cancer, with results expected in 2025.
